semaglutide banned in europe is Off-patent 2026: the next revolution in anti-obesity medications The FDA sent a warning – Novo Nordisk and Hims &

Semaglutide (Wegovy), when used at the 2.4 mg weekly dose for weight management, has demonstrated significant efficacy in large-scale randomised controlled trials

It is FDA-approved for lowering blood sugar levels in type 2 diabetes patients who are taking metformin, sulfonylureas, or a combination of both

Indications: Used primarily to treat vitamin B12 deficiencies due to malabsorption, dietary inadequacies (e.g., in vegans), or certain medical conditions like pernicious anemia

By understanding these risks and working closely with healthcare providers, patients can maximize the benefits of semaglutide while minimizing any adverse effects